Longitudinal Changes in EULAR Sjögren’s Syndrome Patient Reported Index in Routine Clinical Practice

Ji Hyoun Kim¹, You-Jung Ha², Eun Ha Kang², Yeong Wook Song^3,4 and Yun Jong Lee⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁴Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁵Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: SICCA, Sjogren's syndrome and quality of life

Session Information

Date: Monday, November 6, 2017

Title: Sjögren's Syndrome Poster II: Clinical Research

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: This study aimed to investigate the longitudinal changes in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and to study clinical features associated with favorable ESSPRI changes in Korean patients with primary Sjögren’s syndrome (pSS).

Methods:

At baseline and after a median 6.6 [interquartile range, 4.9~8.4] years, 41 pSS patients were evaluated through ESSPRI, EULAR Sjögren’s syndrome disease activity index (ESSDAI), EULAR Sicca Score (ESS), health-related quality of life (HRQOL) questionnaires (SF-36), Xerostomia Inventory (XI), and visual analog scale (VAS) for exocrine and extra-exocrine symptoms. Also, we collected data for used medications and laboratory results. Favorable outcome (F) group was defined as patients who had improved ESSPRI (from baseline ESSPRI ≥5 to follow-up ESSPRI <5) or the maintenance of satisfactory symptom state (ESSPRI <5) and unfavorable (UF) group was those with worsening of ESSPRI (from baseline ESSPRI <5 to follow-up ESSPRI ≥5) or the maintenance of unsatisfactory symptom state (ESSPRI ≥5).

Results: During the follow-up period, ESSPRI was significantly increased from 4.11 [3.22~5.56] to 5.33 [3.50~6.67] (p < 0.05) and SF-36 scores were not changed in pSS patients even though XI scores (p=0.01) and oral dryness (p<0.05) were significantly decreased in the total enrolled patients. Hyper-gamma-globulinemia (p<0.001) and anemia (p<0.05) were improved but ESSDAI was not changed. When compared between F (n=17) and UF (n=24) group, F group exhibited significantly lower VAS levels of oral or eye dryness (both p<0.05), XI scores (p<0.05), and ESS scores (p<0.00) than UF group at baseline. Also, F group had more patients with Raynaud’s phenomenon (19.5% versus 9.8%, p<0.05). In spite that baseline physical component summary (PCS) scores were comparable and F group was less likely to take cholinergic (12.2% versus 46.3%, p=0.001) or immuno-modulatory (7.3% versus 31.7%, p<0.05) drugs, F group showed significantly better PCS scores at final follow-up than UF group (p < 0.001).

Conclusion:

In routine clinical practice, most values for subjective or objective assessments including ESSPRI and HRQOL were not significantly improved during the follow up periods in pSS patients. pSS patients with less severe sicca symptom are more likely to have a favorable course, based on ESSPRI status.

Disclosure: J. H. Kim, None; Y. J. Ha, None; E. H. Kang, None; Y. W. Song, None; Y. J. Lee, None.

To cite this abstract in AMA style:

Kim JH, Ha YJ, Kang EH, Song YW, Lee YJ. Longitudinal Changes in EULAR Sjögren’s Syndrome Patient Reported Index in Routine Clinical Practice [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/longitudinal-changes-in-eular-sjogrens-syndrome-patient-reported-index-in-routine-clinical-practice/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-changes-in-eular-sjogrens-syndrome-patient-reported-index-in-routine-clinical-practice/